SAN DIEGO, Aug. 30, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing site in China. The new Shanghai-based facility enables localized production for Illumina’s gene sequencing instruments and consumables and reflects the growing demand in the Chinese market for Illumina’s systems and products.
Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform, Announces $200 Price Target
Oppenheimer analyst Leland Gershell upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Perform to Outperform and announces $200 price target.
